Allogeneic transplantation provides durable remission in a subset of <scp>DLBCL</scp> patients relapsing after autologous transplantation
Timothy S. Fenske(Medical College of Wisconsin), Mehdi Hamadani(Medical College of Wisconsin), Jonathan E. Brammer(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ernesto Ayala(Mayo Clinic in Florida), Sonali M. Smith(University of Chicago), Sunita Nathan(Rush University Medical Center), Siddhartha Ganguly(University of Kansas Medical Center), Attaphol Pawarode(University of Michigan), Mohamed A. Kharfan‐Dabaja(Jacksonville College), Saurabh Chhabra(Medical College of Wisconsin), Anita D’Souza, Hillard M. Lazarus(University Hospitals of Cleveland), Alessandro Digilio, Sachiko Seo(National Cancer Center Hospital East), Tara M. Graff(Illinois CancerCare), Qaiser Bashir(The University of Texas MD Anderson Cancer Center), Mark Hertzberg(The University of Sydney), Ulrike Bacher(Hattiesburg Clinic), David J. Inwards(Mayo Clinic), Samantha Jaglowski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Nishitha Reddy(Vanderbilt University), Cesar Freytes(The University of Texas at San Antonio Health Science Center), Umar Farooq(Wake Forest University), Andy Chen(Stanford University), Rammurti T. Kamble(Baylor College of Medicine), Kwang Woo Ahn(Medical College of Wisconsin), Yi‐Bin Chen(Massachusetts General Hospital), Mitchell S. Cairo(New York Medical College)
Cited by 134
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k